Pharmaceutical major Cadila Healthcare Ltd., race to develop an indigenous Covid-19 vaccine, is in discussion with potential partners to ramp up production capacity if its candidate passes human clinical trials. Cadila is looking to hire contract manufacturers for an additional 50 to 70 MLN doses of its plasmid DNA vaccine, on top of the 100 million that will come from its own capacity, as per the statement of Managing Director Sharvil Patel. However, ee declined to name the companies and the amount Cadila has invested in developing the vaccine.

Patel’s statement reads -We’re just waiting for second-phase to push that part of the process. We have a lot of interest from people who want to use it for other countries and we will license it out for other markets and countries so we can have more manufacturing beyond India.”

Obtaining and delivering a safe vaccine is a major priority for Prime Minister Narendra Modi in a nation with the world’s largest number of infections after the United States. While a government-backed scientific panel last week predicted that the South Asian country is past the peak of infections and may contain the spread by February, many are concerned of further spikes as a festival season commences ahead of densely populated north India’s cold and polluted winter.
Cadila, which also produces corona virus treatments such as remdesivir, is among a number of Indian companies holding vaccine trials.

In Tuesday’s stock market trading session during mid-noon hours, shares of  CADILA HEALTHCARE LTD  was trading in NSE at Rs.418.75. The stock opened at 420 and touched an intraday high level at 422.45.

Modi calls for quick access to vaccines for citizen

Corona cases decline in-country, many cases surfaced in last 24 hours

Telangana: 582 new corona cases, four deaths reported